

Myocardial Conditions in Prenatal Life

Shabnam Peyvandi, MD MAS

Associate Professor of Pediatrics, Epidemiology & Biostatistics

Associate Director, Fetal Cardiovascular Program

Prenatal Myocardial Conditions:

Two main categories

Acquired

- Maternal Diabetes
- Twin-Twin Transfusion Syndrome (TTTS)
- Autoimmune mediated myocarditis
- Arrhythmias
- Congenital heart disease (Ebstein, aortic stenosis)
- Infection

More Common

Primary

- Cardiomyopathy
 - Inherited
 - Syndromic

Less Common

Prenatal Myocardial Conditions: Acquired

Acquired


- Maternal Diabetes
- Twin-Twin Transfusion Syndrome (TTTS)
- Autoimmune mediated myocarditis
- Arrhythmias
- Congenital heart disease (Ebstein, aortic stenosis)
- Infection

➤ ***Twin-Twin Transfusion Syndrome***


Twin-Twin Transfusion Syndrome

- 10-15% Monochorionic/
Diamniotic twin pairs
- A-A, A-V and V-V connection
- Discordant in growth/amniotic
fluid
- Typical presentation 16-24
weeks


Twin Twin Transfusion Syndrome



Abnormal connections in MC placenta



- Artery from one twin dives into placenta and connects with a vein from the other twin (instead of making a “u-turn” to the same fetus)
- A-V anastomosis
 - Uni-directional



Severity: Quintero Staging

- I: Normal Doppler, normal bladders
- II: Normal Dopplers, no donor bladder
- III: Critically abnormal Dopplers (recipient)
- IV: Hydrops in recipient
- V: Death of one twin


TTTS: Cardiac Manifestations

- High risk of CHD
 - Mostly due to acquired PS
- Cardiac manifestations appear even in early stages
 - Recipient cardiomyopathy


Recipient Twin Cardiomyopathy: Early findings



Fused tricuspid inflow



Abnormal ductus venosus




Recipient Twin Cardiomyopathy: Late findings

- Cardiac Hypertrophy
- Diastolic function pathology (Filling time abnormalities)
- Declining systolic function
- RVOTO, dynamic or valvar (some)





Pathophysiology

- 1) Neuroendocrine dysfunction of placenta with elevated vasoactive mediators (renin-angiotensin, endothelin-III) --> increased afterload to both ventricles
- 2) Reduction in early filling times of both ventricles and hypertrophy
- 3) Impaired LV filling → RV volume loading → dilation → tricuspid regurgitation
- 4) Systolic dysfunction




Treatment Options

- Conservative Management
- Amnioreduction
- Septostomy
- Selective reduction/termination
- Selective laser photocoagulation → Changing the natural history of disease



Cardiac Outcomes

- Post-laser recipient cardiac findings can normalize



Prenatal Myocardial Conditions: Primary Myocardial Disease


Primary

- Cardiomyopathy
 - Genetic (Inherited/De novo)
 - Syndromic
 - Metabolic
 - Mitochondrial

Three examples



**Hypertrophic Cardiomyopathy
RASopathy (Noonan/Costello)
Outcome: TOP**



**Dilated Cardiomyopathy
Compound heterozygote
mutation ACAD9
(mitochondrial function)
Outcome: Fetal demise**



**Dilated Cardiomyopathy
Pathogenic variant TPM1
Outcome: neonatal demise**

Fetal Primary Cardiomyopathy

- Fetal presentation rare
- Single center studies:
 - 38 cases in 17 year period (*Edmonton, Trakmulkichkarn et al, 2022*)
 - 25 cases in 12 year period (*Texas, Ezon et al, 2016*)
 - 50 cases in 12 year period (*Toronto, Weber R et al, 2014*)

Fetal Primary Cardiomyopathy

- High rates of genetic diagnosis
 - 63% overall
 - 76% in current era vs. 38% in older cohort
- High risk for mortality and morbidity
 - Liveborn: 50%
 - Alive at follow-up: 63%
 - No obvious era difference

Table 3 Outcome of 38 cases of fetal cardiomyopathy, overall and according to era of diagnosis

<i>Variable</i>	<i>Overall:</i>			<i>P*</i>
	<i>2003–2019</i> (n = 38)	<i>2003–2012</i> (n = 13)	<i>2013–2019</i> (n = 25)	
Confirmed/strongly suspected genetic etiology	24 (63)	5 (38)	19 (76)	0.04
Outcome				
TOP	10 (26)	2 (15)	8 (32)	0.44
IUD	9 (24)	5 (38)	4 (16)	0.23
Live birth	19 (50)	6 (46)	13 (52)	0.73
Alive at follow-up	12/19 (63)	3/6 (50)	9/13 (69)	0.6
NND	3/19 (16)	1/6 (17)	2/13 (15)	1.00
Late death	4/19 (21)	2/6 (33)	2/13 (15)	0.56

Fetal Primary Cardiomyopathy

- Fetal echo parameters of poor outcome:
 - Hydrops
 - Low Cardiovascular Profile score
 - Moderate AV valve regurgitation



Fetal Primary Cardiomyopathy

- Treatment?
 - Prenatal Digoxin (limited experience)





Table 3 Outcome of 38 cases of fetal cardiomyopathy, overall and according to era of diagnosis

	<i>Overall:</i>			
<i>Variable</i>	2003–2019 (n = 38)	2003–2012 (n = 13)	2013–2019 (n = 25)	P*
Confirmed/strongly suspected genetic etiology	24 (63)	5 (38)	19 (76)	0.04
Outcome				
TOP	10 (26)	2 (15)	8 (32)	0.44
IUD	9 (24)	5 (38)	4 (16)	0.23
Live birth	19 (50)	6 (46)	13 (52)	0.73
Alive at follow-up	12/19 (63)	3/6 (50)	9/13 (69)	0.6
NND	3/19 (16)	1/6 (17)	2/13 (15)	1.00
Late death	4/19 (21)	2/6 (33)	2/13 (15)	0.56

Fetal Primary Cardiomyopathy

- Treatment?
 - Delivery for hydropic fetus:
 - Depends on viability (GA) and neonatal support options
 - Weight appears to be an important factor
 - High center variability



Thank you